BioNTech Results Presentation Deck

Expected Pipeline Milestones in 2022 (1 of 2) BNT162b2 • Data for 4th dose in adults, aged 16 to 65 years Data for 3rd dose in children, aged 5 to <12 years Data for 3-dose regimen in children, aged 6 months to <5 years ● ● Next-Generation COVID-19 vaccines • Data for Omicron-based vaccine (monovalent) Multiple updates: Variant combinations and bivalent vaccines ● 8+ Data Updates Other pipeline programs BNT 161 - Influenza mRNA vaccine ¹ BNT1222 Phase 2 - iNeST in combination w/Pembrolizumab, 1L Melanoma BNT211 Phase 1/2 CAR-T/CLDN6+, multiple solid tumors 34 CLDN, Claudin; NSCLC, non-small cell lung cancer 1 Partnered with Pfizer 2 Partnered with Genentech Timing ongoing ongoing April April 2H 1H 2H 2H BIONTECH

View entire presentation